Selection of Proposals as Approved Research Projects Sample Clauses

Selection of Proposals as Approved Research Projects. The Research Board has the sole, independent authority to select the Proposals for funding under the GoMRI, provided that both the Proposal and the process of selection adhere to both this Agreement and the RFP approved by the Parties; such selection by the Research Board is not subject to consultation with or approval by the Parties. While the Research Board has discretion to determine both the Research Consortia and Research Themes to be explored at each Research Consortium, the Proposals selected must (a) constitute innovative programs of research combining state of the art research techniques with deep technical knowledge of the Gulf of Mexico; and (b) utilize Research Investigators recruited from multiple institutions chosen to provide complementary research capabilities with the greatest strength. Each such approved Proposal, including any discretionary decisions regarding funding made during the course of the peer review process, constitutes an “Approved Research Project.” The GoMRI Administrative Unit shall provide the Research Board with such administrative support for the selection process as is directed by the Research Board. Provided, however, that in no event may the amounts awarded by the Research Board be in excess of the amounts permissible under Sections 2.2 and 2.3.
Sample 1
Selection of Proposals as Approved Research Projects. In advance of Proposal selection, the GoMRI Administrative Unit shall notify the Research Board of the maximum amount of Research Project Costs allocated to that Program Year. Subject to the requirements of Section 5.5 and with the support of the GoMRI Administrative Unit, the Research Board shall then review and select Proposals as Approved Research Projects, that together with any authorized Continuation Funding Requests or amendments to Approved Research Projects described in Sections 3.2.6 and 6, do not exceed the maximum amount of Research Project Costs allocated to that Program Year. The Research Board shall then direct the GoMRI Administrative Unit to (a) notify the Research Consortia and the Parties as to which Proposals have been selected as Approved Research Projects, (b) notify the Research Consortia that have been selected to conduct Approved Research Projects of the identity of the Lead Research Institution as described in Section 4.4, and (c) direct the GoMRI Grant Unit to enter into Grant Agreements with the Research Consortia for the Approved Research Projects, as described in Section 7, provided that the Research Board must approve the appointment of any Research Project Director prior to execution of the Grant Agreement, as set forth in Section 4.5.
Sample 1

Related to Selection of Proposals as Approved Research Projects

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Program The term “

  • Presentation of Potential Target Businesses The Company shall cause each of the Initial Shareholders to agree that, in order to minimize potential conflicts of interest which may arise from multiple affiliations, the Initial Shareholders will present to the Company for its consideration, prior to presentation to any other person or company, any suitable opportunity to acquire an operating business, until the earlier of the consummation by the Company of a Business Combination or the liquidation of the Company, subject to any pre-existing fiduciary obligations the Initial Shareholders might have.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.